Details for Patent: 7,384,978

Title:	Compounds and methods for delivery of prostacyclin analogs
Abstract:	This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula ##STR00001##
Inventor(s):	Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Filing Date:	Nov 22, 2006
Application Number:	11/603,124
Claims:	1. An oral pharmaceutical composition comprising a compound having structure I ##STR00032## wherein, R.sup.1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR.sup.1 are substituted or unsubstituted glycolamide esters; R.sup.2 and R.sup.3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids or proteins, with the proviso that all of R.sup.1, R.sup.2 and R.sup.3 are not H; or enantiomers or pharmaceutically acceptable salts thereof; and and an oral excipient. 2. The composition of claim 1, wherein R.sup.1 is a substituted or unsubstituted benzyl group. 3. The composition of claim 2, wherein R.sup.1 is CH.sub.2C.sub.6H.sub.5. 4. The composition of claim 1, wherein OR.sup.1 is a substituted or unsubstituted glycolamide ester, R.sup.1 is --CH.sub.2CONR.sup.4R.sup.5, R.sup.4 and R.sup.5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, --(CH.sub.2).sub.mCH.sub.3, --CH.sub.2OH, and --CH.sub.2(CH.sub.2).sub.nOH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4. 5. The composition of claim 4, wherein one or both of R.sup.4 and R.sup.5 are independently selected from the group consisting of H, --OH, --CH.sub.3, or --CH.sub.2CH.sub.2OH. 6. The composition of claim 4, wherein both of R.sup.4 and R.sup.5 are H, --OH, --CH.sub.3, or --CH.sub.2CH.sub.2OH. 7. The composition of claim 1, wherein one or both of R.sup.2 and R.sup.3 are H. 8. The composition of claim 1, wherein R.sup.2 and R.sup.3 are independently selected from phosphate and groups wherein OR.sup.2 and OR.sup.3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapeptides. 9. The composition of claim 8, wherein only one of R.sup.2 or R.sup.3 is a phosphate group. 10. The composition of claim 8, wherein R.sup.2 and R.sup.3 are independently selected from groups wherein OR.sup.2 and OR.sup.3 are esters of amino acids. 11. The composition of claim 10, wherein one or both of R.sup.2 and R.sup.3 are esters of glycine or alanine. 12. The composition of claim 1, wherein one of R.sup.2 and R.sup.3 are H. 13. The composition of claim 10, wherein R.sup.2is H. 14. The composition of claim 1, wherein R.sup.1 is H.